Influence of the susceptibility genes apolipoprotein E-epsilon 4 and apolipoprotein E-epsilon 2 on the rate of disease expressivity of late-onset Alzheimer's disease
- PMID:7763336
Influence of the susceptibility genes apolipoprotein E-epsilon 4 and apolipoprotein E-epsilon 2 on the rate of disease expressivity of late-onset Alzheimer's disease
Abstract
Apolipoprotein E-epsilon 4 (APOE4, gene; apoE4, protein) is a susceptibility gene or risk factor for Alzheimer's disease. The genetic relevance of APOE4 has been widely confirmed. The APOE gene is not a disease locus, with specific mutations causing Alzheimer disease. Allelic variations at the APOE locus affect the rate of disease progression. The association of specific inherited APOE alleles with age of onset distributions describes biological effects based on genotype. The inheritance of polymorphic genes with single amino acid differences between apoE4 and apoE3 (and between apoE3 and apoE2) at the protein level is associated with differences in the mean age of disease onset spanning almost two decades. The isoform-specific metabolism of apoE resulting in a faster rate of disease expression can now be studied with the expectation that genetically relevant processes are being investigated. There is now an opportunity to develop theories directed at the genetically relevant apoE metabolism that can significantly delay disease expression.
Similar articles
- Apolipoprotein E and Alzheimer's disease.Strittmatter WJ, Roses AD.Strittmatter WJ, et al.Annu Rev Neurosci. 1996;19:53-77. doi: 10.1146/annurev.ne.19.030196.000413.Annu Rev Neurosci. 1996.PMID:8833436Review.
- Allelic association but only weak evidence for linkage to the apolipoprotein E locus in late-onset Swedish Alzheimer families.Liu L, Forsell C, Lilius L, Axelman K, Corder EH, Lannfelt L.Liu L, et al.Am J Med Genet. 1996 May 31;67(3):306-11. doi: 10.1002/(SICI)1096-8628(19960531)67:3<306::AID-AJMG7>3.0.CO;2-K.Am J Med Genet. 1996.PMID:8725748
- Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). Relevance to Alzheimer's disease.Aleshkov S, Abraham CR, Zannis VI.Aleshkov S, et al.Biochemistry. 1997 Aug 26;36(34):10571-80. doi: 10.1021/bi9626362.Biochemistry. 1997.PMID:9265639
- APOE epsilon 3/ epsilon 4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer's disease diagnosis.Fukumoto H, Ingelsson M, Gårevik N, Wahlund LO, Nukina N, Yaguchi Y, Shibata M, Hyman BT, Rebeck GW, Irizarry MC.Fukumoto H, et al.Exp Neurol. 2003 Sep;183(1):249-53. doi: 10.1016/s0014-4886(03)00088-8.Exp Neurol. 2003.PMID:12957508
- Apolipoprotein E isoforms in Alzheimer's disease pathology and etiology.Baum L, Chen L, Ng HK, Pang CP.Baum L, et al.Microsc Res Tech. 2000 Aug 15;50(4):278-81. doi: 10.1002/1097-0029(20000815)50:4<278::AID-JEMT5>3.0.CO;2-T.Microsc Res Tech. 2000.PMID:10936880Review.
Cited by
- DNA methylation, a hand behind neurodegenerative diseases.Lu H, Liu X, Deng Y, Qing H.Lu H, et al.Front Aging Neurosci. 2013 Dec 5;5:85. doi: 10.3389/fnagi.2013.00085.Front Aging Neurosci. 2013.PMID:24367332Free PMC article.Review.
- ApoE promotes the proteolytic degradation of Abeta.Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE.Jiang Q, et al.Neuron. 2008 Jun 12;58(5):681-93. doi: 10.1016/j.neuron.2008.04.010.Neuron. 2008.PMID:18549781Free PMC article.
- The effects of aerobic training before and after the induction of Alzheimer's disease on ABCA1 and APOE mRNA expression and the level of soluble Aβ1-42 in the hippocampus of male Wistar rats.Sarlak Z, Moazzami M, Attarzadeh Hosseini M, Gharakhanlou R.Sarlak Z, et al.Iran J Basic Med Sci. 2019 Apr;22(4):399-406. doi: 10.22038/ijbms.2018.32911.7860.Iran J Basic Med Sci. 2019.PMID:31168344Free PMC article.
- Proteomic analysis of APOEε4 carriers implicates lipid metabolism, complement and lymphocyte signaling in cognitive resilience.Walker KA, An Y, Moghekar A, Moaddel R, Duggan MR, Peng Z, Tian Q, Pilling LC, Drouin SM, Espeland MA, Rapp SR, Hayden KM, Shadyab AH, Casanova R, Thambisetty M, Rapp PR, Kapogiannis D, Ferrucci L, Resnick SM.Walker KA, et al.Mol Neurodegener. 2024 Oct 31;19(1):81. doi: 10.1186/s13024-024-00772-2.Mol Neurodegener. 2024.PMID:39482741Free PMC article.
- Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls.Morra JH, Tu Z, Apostolova LG, Green AE, Avedissian C, Madsen SK, Parikshak N, Hua X, Toga AW, Jack CR Jr, Schuff N, Weiner MW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative.Morra JH, et al.Hum Brain Mapp. 2009 Sep;30(9):2766-88. doi: 10.1002/hbm.20708.Hum Brain Mapp. 2009.PMID:19172649Free PMC article.
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Medical
Miscellaneous